Search research articles
Contact Us
Filters
Showing results (71-80 of 110) with videos related to
Page
of 11
Sort By:
Cancer Immunology, Immunotherapy : CII
|
May 1, 2020
Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature
Tsubasa Watanabe, Elke Firat, Jutta Scholber, et al.
JCO Precision Oncology
|
January 20, 2022
Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma
Jan Braune, Laura Keller, Florian Schiller, et al.
The Journal of Clinical Investigation
|
October 21, 2014
BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia
Niuscha Yaktapour, Frank Meiss, Justin Mastroianni, et al.
Oncotarget
|
October 23, 2018
The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study
Julia K Tietze, Andrea Forschner, Carmen Loquai, et al.
BMC Cancer
|
May 30, 2021
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Stéphane Dalle, Laurent Mortier, Pippa Corrie, et al.
JCI Insight
|
March 4, 2020
MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors
Dominik Marschner, Martina Falk, Nora Rebeka Javorniczky, et al.
Diagnostics (Basel, Switzerland)
|
August 5, 2020
Personalized Treatment Selection and Disease Monitoring Using Circulating Tumor DNA Profiling in Real-World Cancer Patient Management
Julius Wehrle, Ulrike Philipp, Martina Jolic, et al.
Journal of Cancer Research and Clinical Oncology
|
May 14, 2024
Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors' perspective
Katharina C Kähler, Ralf Gutzmer, Yenny Angela, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
March 29, 2019
Primär kutanes diffus-großzelliges B-Zell-Lymphom, NOS oder leg type: klinische, morphologische und prognostische Unterschiede
Moritz Felcht, Claus-Detlev Klemke, Jan Peter Nicolay, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
March 10, 2019
Primary cutaneous diffuse large B-cell lymphoma, NOS and leg type: Clinical, morphologic and prognostic differences
Moritz Felcht, Claus-Detlev Klemke, Jan Peter Nicolay, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 110) with videos related to
Sort By:
Page
of 11
Cancer Immunology, Immunotherapy : CII
|
May 1, 2020
Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature
Tsubasa Watanabe, Elke Firat, Jutta Scholber, et al.
JCO Precision Oncology
|
January 20, 2022
Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma
Jan Braune, Laura Keller, Florian Schiller, et al.
The Journal of Clinical Investigation
|
October 21, 2014
BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia
Niuscha Yaktapour, Frank Meiss, Justin Mastroianni, et al.
Oncotarget
|
October 23, 2018
The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study
Julia K Tietze, Andrea Forschner, Carmen Loquai, et al.
BMC Cancer
|
May 30, 2021
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Stéphane Dalle, Laurent Mortier, Pippa Corrie, et al.
JCI Insight
|
March 4, 2020
MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors
Dominik Marschner, Martina Falk, Nora Rebeka Javorniczky, et al.
Diagnostics (Basel, Switzerland)
|
August 5, 2020
Personalized Treatment Selection and Disease Monitoring Using Circulating Tumor DNA Profiling in Real-World Cancer Patient Management
Julius Wehrle, Ulrike Philipp, Martina Jolic, et al.
Journal of Cancer Research and Clinical Oncology
|
May 14, 2024
Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors' perspective
Katharina C Kähler, Ralf Gutzmer, Yenny Angela, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
March 29, 2019
Primär kutanes diffus-großzelliges B-Zell-Lymphom, NOS oder leg type: klinische, morphologische und prognostische Unterschiede
Moritz Felcht, Claus-Detlev Klemke, Jan Peter Nicolay, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
March 10, 2019
Primary cutaneous diffuse large B-cell lymphoma, NOS and leg type: Clinical, morphologic and prognostic differences
Moritz Felcht, Claus-Detlev Klemke, Jan Peter Nicolay, et al.
Page
of 11